Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non‐nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high‐performance liquid chromatography
- 22 June 2005
- journal article
- research article
- Published by Wiley in Biomedical Chromatography
- Vol. 20 (1) , 28-36
Abstract
We report the development of a simple, economical and reliable chromatographic method for the simultaneous determination of six HIV protease inhibitors (PIs; amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and the non‐nucleoside reverse transcriptase inhibitor (NNRTI; efavirenz) in human plasma. After extraction from plasma with an ethyl acetate–acetonitrile mixture, the analytes were separated on a phenyl column with a gradient of acetonitrile and phosphate solutions, and detected at three ultraviolet wavelengths. Calibration curves were linear over the range 0.025–15 µg[sol ]mL for saquinavir and 0.05–15 µg[sol ]mL for the other analytes. The accuracies ranged from −6.9% to +7.6%, and the intra‐assay and inter‐assay precisions were <9.2 and <11.8%, respectively. Our method, covering most of the PIs and NNRTIs currently used, facilitates ready therapeutic drug monitoring in hospital laboratories. Copyright © 2005 John Wiley & Sons, Ltd.Keywords
This publication has 25 references indexed in Scilit:
- High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasmaJournal of Chromatography B, 2004
- Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometryJournal of Mass Spectrometry, 2003
- Position Paper on Therapeutic Drug Monitoring of Antiretroviral AgentsAIDS Research and Human Retroviruses, 2002
- Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics studyThe Lancet, 2002
- Therapeutic Drug Monitoring of HIV Protease Inhibitors Using High-Performance Liquid Chromatography With Ultraviolet or Photodiode Array DetectionTherapeutic Drug Monitoring, 2001
- HIV chemotherapyNature, 2001
- Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus‐infected patients with chronic liver diseaseBritish Journal of Clinical Pharmacology, 2000
- Using Pharmacokinetics to Optimize Antiretroviral Drug-Drug Interactions in the Treatment of Human Immunodeficiency Virus InfectionClinical Infectious Diseases, 2000
- Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 InhibitionClinical Pharmacokinetics, 2000
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998